Low-density lipoproteins in human serum competitively inhibit the binding and entry of vesicular stomatitis virus

Read full text Summarise with VIRAT
Authors: Rianna Vandergaast, Samantha Johnson, Christopher M. Ziegler, Gopal Naik Nenavath, Luke Schnebeck, Riya Narjari, Stephen J. Russell
Cited by: 0
References: 49

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Vesicular stomatitis virus (VSV) is a promising anticancer agent but rapidly loses its infectivity in human serum. Here, we demonstrate that low-density and very low-density lipoproteins (LDLs and VLDLs) compete with VSV-G-displaying vectors for occupancy of cellular LDL receptors (LDLRs). Infectivity of VSV-G-displaying vectors was reduced two- to three-logs in the presence of heat-inactivated human serum but not if the serum was depleted of lipoproteins. The inhibitory effect was replicated in serum-free media supplemented with physiological concentrations of purified lipoprotein particles that contain the LDLR-binding protein Apo B-100, and the degree of inhibition correlated with the concentration of LDL or VLDL. When VSV-G was retargeted to the epidermal growth factor receptor, competitive inhibition by human serum or by LDL/VLDL was no longer observed. Similar results were obtained when VSV-G was retargeted to other receptors. Our findings demonstrate that serum LDL and VLDL competitively block the entry of VSV-G-displaying viral particles, but this barrier for in vivo delivery can be circumvented through a display of a receptor-targeting ligand on VSV-G.

Fields of Study & Subjects

Virus-based gene therapy research RNA Interference and Gene Delivery Nanoparticle-Based Drug Delivery

Publication details

Journal / source
Molecular Therapy Advances
Volume
34
Issue
2
Pages
201721–201721
Publication date
19 March 2026
Language
EN